EpiBiologics is advancing bispecific antibodies that selectively degrade membrane and soluble proteins, including GPCRs. Our EpiTAC platform leverages a novel atlas of tissue-selective degrader receptors to drive deep and durable efficacy. The company was founded in 2022 based on pioneering work from Dr. Jim Wells at UCSF. Headquartered in the SF Bay Area, EpiBiologics is backed by leading healthcare investors and building a clinical stage pipeline for oncology and immunology. For more information, please visit epibiologics.com and follow us on LinkedIn.
| Website | https://www.epibiologics.com/ |
| Employees | 50 (38 on RocketReach) |
| Address | 1900 Alameda de Las Pulgas, San Mateo, California 94402, US |
| Industry | Biotechnology Research |
| Keywords | Protein Degradation, Therapeutic Proteins, Biotechnology, Drug Discovery, Protein Therapeutics, Pharmaceutical Research, Molecular Biology, Biologics, Targeted Therapy, Protein Engineering, Next Generation Therapeutics, Innovative Medicines, Biopharmaceutical, Drug Development, Precision Medicine, Life Sciences, Clinical Development, Biotechnology Platform |
| Competitors | Roche, Novartis, Merck & Co., Inc., Pfizer, AstraZeneca, Genentech, Amgen, Regeneron, Gilead Sciences, Biogen +46 more (view full list) |
Looking for a particular EpiBiologics employee's phone or email?
Craig Lichtenstein is the COO of EpiBiologics.
38 people are employed at EpiBiologics.
EpiBiologics is based in San Mateo, California.